Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia
The grant will enable leading international researchers to complete a clinical trial comparing the two most common treatment methods for preventing leg amputation among people with critical limb ischaemia.
Critical limb ischaemia is a serious and debilitating disease that affects about 22 million people globally, and these are often people with diabetes and/or chronic kidney disease. It is estimated that the yearly cost of treating critical limb ischemia in the United States is as high as 12 billion dollars, and more than 10 million procedures are carried out annually worldwide to avoid amputation.
